Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Takeo Arita"'
Autor:
Sei Yoshida, Tomoyasu Ishikawa, Masanori Okaniwa, Katherine Galvin, Elizabeth Carideo, Jouhara Chouitar, Jill Donelan, Shuntarou Tsuchiya, Takeo Arita, Akito Nakamura
PDF file - 614K, Cellular effects of TAK-632, vemurafenib, and TAK-733 on MAPK signaling (S1); Model describing RAF paradoxical activation (S2); Effects of TAK-632 and vemurafenib on BRAF kinase activity (S3); Reversibility of TAK-632 and vemurafenib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdcaf05c51ce47ecf2912f5b05346bc5
https://doi.org/10.1158/0008-5472.22398855.v1
https://doi.org/10.1158/0008-5472.22398855.v1
Autor:
Sei Yoshida, Tomoyasu Ishikawa, Masanori Okaniwa, Katherine Galvin, Elizabeth Carideo, Jouhara Chouitar, Jill Donelan, Shuntarou Tsuchiya, Takeo Arita, Akito Nakamura
PDF file - 103K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6e57be0280b50c7eb627a772539273
https://doi.org/10.1158/0008-5472.22398852
https://doi.org/10.1158/0008-5472.22398852
Autor:
Sei Yoshida, Tomoyasu Ishikawa, Masanori Okaniwa, Katherine Galvin, Elizabeth Carideo, Jouhara Chouitar, Jill Donelan, Shuntarou Tsuchiya, Takeo Arita, Akito Nakamura
PDF file - 119K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed2773d2e203edffde7e16a28cb8d4c
https://doi.org/10.1158/0008-5472.22398858.v1
https://doi.org/10.1158/0008-5472.22398858.v1
Autor:
Masaki Shimoji, Michael Gmachl, Toshiki Takemoto, Toshio Fujino, Akira Hamada, Marco H. Hofmann, Junichi Soh, Takeo Arita, Shuta Ohara, Takamasa Koga, Masato Chiba, Masaya Nishino, Tetsuya Mitsudomi, Kenichi Suda
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(8)
Introduction KRAS mutations have been recognized as undruggable for many years. Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed promising results in metastatic NSCLC. Nev
Autor:
Takahito Hara, Satoshi Kitazawa, Misa Iwatani, Hitoshi Miyashita, Ryutaro Adachi, Yukiko Yamamoto, Megumi Morimoto, Takeo Arita, Sou Sakamoto, Takaharu Hirayama, Kazumasa Miyamoto
Publikováno v:
Biochemical and Biophysical Research Communications. 488:648-654
Protein translation is highly activated in cancer tissues through oncogenic mutations and amplifications, and this can support survival and aberrant proliferation. Therefore, blocking translation could be a promising way to block cancer progression.
Autor:
Michael G. Klein, Taisuke Katoh, Etsurou Watanabe, Gyorgy Snell, Yoshihisa Nakada, Hideyuki Nakagawa, Tetsuya Tsukamoto, Takeo Arita, Hiroki Hayashi, Bi-Ching Sang, Takafumi Takai, Hua Zou, Hideyuki Mototani, Takafumi Yukawa
Publikováno v:
Bioorganic & Medicinal Chemistry. 24(11):2466-2475
A high-throughput screening campaign helped us to identify an initial lead compound (1) as a protein kinase C-θ (PKCθ) inhibitor. Using the docking model of compound 1 bound to PKCθ as a model, structure-based drug design was employed and two regi
Autor:
Katherine Galvin, Shuntarou Tsuchiya, Jouhara Chouitar, Sei Yoshida, Tomoyasu Ishikawa, Jill Donelan, Elizabeth Carideo, Masanori Okaniwa, Takeo Arita, Akito Nakamura
Publikováno v:
Cancer Research. 73:7043-7055
The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of melanoma cells. Somatic mutations in BRAF and NRAS are frequently observed in melanoma. Recently, the BRAF inhibitors vemurafenib and
Autor:
Yoshitaka Inui, Masanori Okaniwa, Takeo Arita, Terufumi Takagi, Tomohiro Kawamoto, Bi-Ching Sang, Noriko Uchiyama, Jason Yano, Kathleen Aertgeerts, Shunichirou Tsutsumi, Sei Yoshida, Masato Yabuki, Masaaki Hirose, Akihiko Sumita, Tomoyasu Ishikawa, Tsuneaki Tottori, Akito Nakamura
Publikováno v:
Journal of medicinal chemistry. 56(16)
With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivatives based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor 1 and developed a regioselective cyclization
Autor:
Sei Yoshida, Takeo Arita, Masato Yabuki, Terufumi Takagi, Tomohiro Kawamoto, Shunichirou Tsutsumi, Tomoyasu Ishikawa, Masanori Okaniwa, Akihiko Sumita, Tomohiro Ohashi, Takashi Imada, Tohru Miyazaki, Bi-Ching Sang, Yuta Tanaka, Jason Yano, Masaaki Hirose, Kathleen Aertgeerts
Publikováno v:
Bioorganicmedicinal chemistry. 20(18)
Our aim was to discover RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors that possess strong activity and sufficient oral absorption, and thus, we selected a 5-amino-linked thiazolo[5,4-d]pyrimidine derivative as the lead compoun
Autor:
Tomohiro Ohashi, Shunichirou Tsutsumi, Masanori Okaniwa, Masato Yabuki, Tomoyasu Ishikawa, Akihiko Sumita, Terufumi Takagi, Takashi Imada, Takeo Arita, Tohru Miyazaki, Tomohiro Kawamoto, Keiko Higashikawa, Yoshitaka Inui, Sei Yoshida
Publikováno v:
Bioorganicmedicinal chemistry. 20(15)
As an alternative to the previously reported solid dispersion formulation for enhancing the oral absorption of thiazolo[5,4-b]pyridine 1, we investigated novel N-acyl imide prodrugs of 1 as RAF/vascular endothelial growth factor receptor 2 (VEGFR2) i